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I would like to make a strong case and suggest a new 
indication for an old drug which has been known for 
its strong bactericidal and virucidal properties. The 
drug is povidone-iodine (PVP-I). It has been used 
extensively over a long period of time as a strong 
antiseptic agent in different forms. In all these 
forms, it is used as a topical agent and has been 
found very efficacious and safe.[1-11]
In the most common form, PVP-I is used as a 
surgical scrub and/or a surgical prep for sterilizing 
the skin for a major or minor surgical operation 
or some other invasive procedures such as local 
injection, aspiration, or cardiac catheterization. A 
10% solution is used extensively for surgical prep 
and causes minimal skin irritation, especially when 
residual paint is washed off at the completion of 
the procedure. It is also used commonly as an over-
the-counter agent for treating minor wounds and 
burns. 5% betadine (PVP-I) ointment is also used for 
this purpose and it acts as an effective antiseptic 
agent without any injurious or untoward effect on 
the skin.
PVP-I is used to sterilize the conjunctiva and 
cornea in the eye for cataract surgery. It is 
also used as an eye wash as a cleansing and 
antibacterial agent after accidental exposure to 
potential contaminants. It is used by dentists and 
oral surgeons to cleanse and sterilize the mucosal 
lining in the oropharyngeal cavity and on the gums. 
It is used by ENT surgeons to cleanse and sterilize 
the skin and mucosa in the nose and nasopharynx. 
Urologists and OBGYNs use PVP-I solution or 
ointment to apply to urogenital skin and mucosa 
as a sterilizing and antibacterial agent. It is also 
used as a vaginal douche by women.
Intraoperatively, PVP-I solution has been extensively 
used by general surgeons to cleanse and wash 
heavily contaminated peritoneal cavity due to 
general peritonitis resulting from perforated viscus. 
They very frequently cleanse the cut edges of the 
transected bowel with PVP-I soaked swabs with 
the intention of not only cleaning but sterilizing 
them before reanastomosis to ensure good healing 
and minimize the chances of local infection and 
anastomotic leak.
Thoracic surgeons wash pleural cavity with 
PVP-I solution after pulmonary and esophageal 
resections and clean the cut edges of bronchi 
and esophagus with betadine solution before 
performing anastomosis. In case of empyema or 
subphrenic abscess, they use copious amounts 
of PVP-I solution to clean and disinfect these 
cavities after proper drainage. During pulmonary 
resections, they frequently use betadine soaked 
gauze to temporarily cover the cut surface of 
the lung. About 10% PVP-I solution apparently 
causes no chemical injury to the cut surface of the 
pulmonary parenchyma or pleura.
Iodine has a strong bactericidal, sporicidal, 
fungicidal, protozoacidal, and virucidal properties. 
Most bacteria are killed within 10 min by 0.0002% 
solution and in 10 s by 1% solution. In PVP-I, iodine 
is complexed with the pyrrolidone nitrogen of 
polyvinyl-pyrrolidone. In 10% PVP-I which contains 
1% available iodine, the free iodine concentration is 
only 8 micromoles (0.001% free iodine). When PVP-I 
is diluted to 0.1%, the free iodine concentration 
rises to 80 micromoles because of dissociation of 
the complex. Bactericidal activity is thus higher at 
0.1% than at 10% concentration.[11]
Topically applied, PVP-I can kill bacteria and viruses 
very fast – within a matter of seconds – without 
causing any apparent injury to the skin, mucous 
membranes, or serosal surfaces such as pleura and 
peritoneum. It is not injurious to conjunctiva or 
cornea either. Pharmacologically speaking, a very 
dilute solution with low concentration of PVP-I has 
stronger bactericidal and virucidal effect.[11]
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Based on all this, I conjecture to hypothesize that 
air actively inhaled through a very dilute solution 
of PVP-I (similar to a hookah) will be effective in 
killing the coronavirus (CoV)-2 without causing any 
significant injury to tracheobronchial tree or lung 
alveoli. This mode of application will essentially be 
topical in nature. If there is a chemical injury, it will 
be minor and reversible in my opinion. There will be 
some possible absorption from the alveoli into the 
blood, but the dose will be so small that it should 
cause no systemic effect or toxicity.[4,5]
In the following paragraphs, I will describe 
the dosage and the method of instituting this 
treatment as I see fit at this moment. With time and 
experience, we will learn more and make necessary 
adjustments and/or modifications.
Povidone-iodine hookah will consist of a small bottle 
or flask with a stopper with two holes. Through one 
hole, a small tube will enter and go down to just 
above the bottom of the bottle. This tube will be 
called air tube and its upper end will be just above 
the stopper. The second tube will be called hookah 
tube and it will enter the bottle through the second 
hole in the stopper, and it will project into the bottle 
for only a centimeter or two below the stopper. 
Its outer end will be connected to a flexible tube 
(preferably made of polyethylene) with a mouth 
piece at its end similar to that of a hookah.
The hookah bottle will be filled up to about one-
third capacity with 1% PVP-I solution using sterile 
water to make it. The air tube will be adjusted up 
or down to leave about 1 cm length submerged in 
the PVP-I solution. To use the hookah, you will first 
exhale fully and then hold the mouth piece between 
the lips tightly. Immediately, thereafter, you will 
suck the air from the hookah bottle with a deep 
inhalation. You will then hold the breath for a few 
seconds and exhale slowly through the nose. Then, 
you will repeat the process with a second deep puff 
and again hold the breath for a few seconds before 
slowly letting it out through the nose. A total of 
five puffs will make one dose. Someone suffering 
from COVID-19 who is able to breathe normally the 
total daily dosage will be one dose every hour or so 
during the day for a total of 10 doses. In most cases, 
a 4–5 days course of this therapy will be enough 
to kill the virus adequately. In some cases, 7 days 
treatment may be needed.
Now, the basis and the rationale of this dosage: An 
adult male normally has a tidal volume of about 
500 mL at rest. With a deep puff, he will presumably 
inhale twice as much that is 1000 mL. One cubic 
meter of air contains about 20 g of water at 100% 
relative humidity at room temperature. In other 
words, 1000 L (1 m3) of air will hold about 20 g of 
water at 100% relative humidity. Hence, 1 L of air 
at 100% humidity at room temperature will contain 
20 mg of water. All the air being inhaled from the 
hookah bottle is coming through 1% PVP-I solution 
and should have 100% relative humidity. One liter 
of this air contains 20 mg of water with 1% PVP-I 
in it. That comes to 0.2 mg of PVP-I in each hookah 
puff. Hence, five puffs will provide a total of 1 mg 
of PVP-I. A total daily dosage of 10 hookah sessions 
will provide a total of 10 mg.
Inhaled air with each puff will in succession come in 
contact with the mucosal lining of mouth, pharynx, 
larynx, trachea, entire bronchial tree with its eight or 
nine generations down to terminal, and respiratory 
bronchioles and finally alveoli. Povidone-iodine 
dissolved in water molecules being carried by the 
inhaled air with 100% relative humidity will be 
very thinly painted on all these mucosal surfaces 
and finally the alveoli. It will either start killing the 
CoV or make it incompetent to multiply in all these 
areas.[8] During exhalation, the mucosal lining of 
nasopharynx and nose will be similarly painted with 
the residual amount of PVP-I. Five puffs, hopefully, 
will provide adequate amount of PVP-I to start 
the virucidal action, and 10 such sessions during 
the course of one day will be enough. A variation 
of this dosage schedule will be using 2% PVP-I 
solution in the hookah bottle and taking five puffs 
every 2–3 h for a total of five sessions per day. To 
find a safe and effective dosage schedule, we will 
obviously need to try a few variations. In very sick 
patients on mechanical ventilation, a nebulizer will 
be used to deliver an appropriate dose through the 
endotracheal or tracheostomy tube.
Since there is no effective therapy for COVID-19, the 
hypothesis outlined above must be put to test as 
soon as possible. Safety studies can be performed 
in animals and/or human volunteers in a matter 
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of days or weeks and if this therapy is found to be 
safe, it can be put to clinical trials or even clinical 
use immediately.
Being a pathologist, a general surgeon and a thoracic 
surgeon and having used PVP-I in thousands of 
surgical cases over a period of 40 plus years, I feel 
fairly confident that my hypothesis will pass the 
test. If that happens, we would have found a simple 
and inexpensive therapeutic measure for COVID-19.
Since I was convinced about the efficacy of this 
treatment, the only remaining question in my 
mind was about its safety. So I made a simple 
hookah using a glass bottle, 1% PVP-I solution and 
two straws going through a make shift cellophane 
airtight lid. Then, I exhaled fully and took a deep 
puff of air from the straw coming out of the upper 
part of the bottle. I could hear the bubbling sound 
like in a hookah. For this puff, I used my nearly full 
inspiratory capacity and must have inhaled at least 
2000 mL of air. After two or three normal breaths 
each time, I repeated the process for 4 more 
times thus making a total of five puffs during the 
course of 1–2 min. This was twice the amount of 
dose recommended above. My oxygen saturation 
measured by a pulse oximeter before this exercise 
was 96–98% and remained unchanged 1 min, 5 min, 
1 h, and 4 h after this exercise. My heart rate also 
remained the same, 72–75/min. These parameters 
showed no change in 24 h and I did not experience 
any untoward symptoms.
In view of the raging pandemic which has already 
claimed over 250,000 lives in the U.S. and close to 
2 million lives worldwide, it is my recommendation 
that physicians taking care of patients with 
COVID-19 should give this treatment a try. I think 
that they have the discretionary authority to use 
medicines for “off label” indications under special 
circumstances, if in their opinion, potential benefits 
outweigh potential risks and the patient agrees. 
The Food and Drug Administration and similar 
health agencies in other countries should allow 
the use of this treatment under the umbrella of 
“Compassionate Use and/or Expanded Access 
Mechanism for Drugs.” For very sick patients being 
maintained on ventilators, I would suggest nebulizer 
treatment with 1% PVP-I solution for 2 min every 
1–2 h depending on the extent of pulmonary 
involvement and adjust it up or down based on the 
response to this therapy. I must confess this dose 
recommendation is somewhat intuitive on my part.
If PVP-I hookah therapy works, we would have 
found a new and inexpensive treatment for not only 
COVID-19 but also quite possibly for many other 
respiratory infections caused by viruses, bacteria, 
and fungi. It will work just as well against the 
variants of CoV (severe acute respiratory syndrome 
CoV [SARS-COV-2]) and other mutated strains. 
Influenza caused by the flu virus should respond 
to this therapy equally well, as should many other 
respiratory infections.
The ease with which a working hookah bottle can 
be made and the availability of PVP-I all over the 
world will make it possible for physicians around 
the globe to successfully use this therapy for their 
patients. They will need to make sure that there 
is no mix up or confusion between the hookah 
tube and the air tube and that their patients will 
always inhale from the hookah tube and not the 
air tube. Accidental sucking from the air tube may 
cause aspiration of PVP-I solution into the lungs 
and severe pneumonia. This must be avoided at all 
costs. Patients who are allergic to iodine will not be 
able to use this treatment.
Vaccines for CoV, SARS-COV-2, have been made with 
unprecedented speed and are being rolled out as 
fast as humanly possible. It will still take many years 
to inoculate the entire population on the planet. We 
do not know how long the immunity will last after 
vaccination. Nor do we know if this virus will mutate 
or keep on mutating into new strains requiring new 
vaccines in the future. No one can predict about 
the eventual outcome of this pandemic or future 
epidemics caused by respiratory viruses. Having an 
effective antiviral therapy for respiratory viruses, 
therefore, is of paramount importance.
It behooves the physician and scientific community 
around the world to put the hypothesis presented 
above to test, and hopefully find in it, a cure for 
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